AM Chemicals LLC entered into an agreement with Glen Research whereby a license to commercialize (for research puropses only) selected GalNAc phosphoramidites and GalNAc solid supports for oligonucleotide synthesis and applications has been granted.
AM Chemicals LLC entered into a license and supply agreement with Aligos Therapeutics whereby an exclusive license for the right to the use of specific constructs for oligonucleotide therapeutic applications has been granted.
AM Chemicals LLC entered into a license and supply agreement with Olix Pharmaceuticals whereby an exclusive license for the right to the use of selected GalNAc-modified phosphoramidites and solid supports for liver targeting strategies has been granted.
An oligonucleotide compound containing a GalNAc linker licensed from AM Chemicals is currently in Phase 1 clinical trials.
AM Chemicals LLC entered into a license agreement with GeneLink whereby a non-exclusive license for the right to manufacture, market and sell oligonucleotide conjugates using selected GalNAc-modified phosphoramidites and solid supports has been granted.